Evolocumab before PCI for high-risk MI reached LDL targets in 82%, but outcomes at a year were unchanged

Design

Phase 4 randomised trial, open label, blinded endpoint adjudication

Population

2,161 adults with high-risk STEMI or NSTEMI undergoing PCI, 48 sites

Primary outcome

LDL below 55 mg/dL with 50% reduction at 12 months

Effect

82% vs 40% (OR 5.54); death or CV admission 14.6% vs 15.4% (OR 0.94, 0.73 to 1.19)

AMUNDSEN, a phase 4 randomised trial with open treatment and blinded endpoint adjudication in JAMA (August 2026), gave evolocumab 140 mg every two weeks for a year, first dose before PCI, on top of high-intensity oral therapy, to 1,087 patients with high-risk STEMI or NSTEMI, against standard care in 1,074.

The LDL target — below 55 mg/dL and at least a 50% fall — was met at 12 months in 82% with evolocumab against 40% with standard care (adjusted OR 5.54, 95% CI 4.50 to 6.82). Median LDL at six weeks was 16 against 56 mg/dL. Death or unplanned cardiovascular admission at 12 months occurred in 14.6% against 15.4% (adjusted OR 0.94, 0.73 to 1.19).

One year is too short to see the benefit of lower LDL on atherosclerotic events, so this does not argue against early intensive lowering. What it does argue against is an acute 'pleiotropic' benefit of giving a PCSK9 inhibitor in the catheter laboratory.

The practical message is the stepwise one: start high-intensity statin with ezetimibe early, check LDL at four to six weeks, and add a PCSK9 inhibitor for those not at target.

• Start high-intensity statin, with ezetimibe where needed, before discharge after MI
• Recheck LDL at four to six weeks and escalate if not below 55 mg/dL
• Do not give a PCSK9 inhibitor in the catheter laboratory expecting an acute plaque benefit
• Reserve early PCSK9 inhibition for patients unlikely to reach target on oral therapy
• Weigh cost: in India PCSK9 inhibitors remain expensive for most patients

Why it matters

It answers whether 'strike early and strong' with a PCSK9 inhibitor buys anything in the first year — it bought LDL control, not events.

Don't overread it

One year was too short to test whether earlier LDL control reduces long-term events.

The statistics, in plain English

An odds ratio of 5.54 for reaching target is a very large effect on a laboratory measure. The clinical odds ratio of 0.94 has a confidence interval of 0.73 to 1.19 — compatible with a 27% reduction or a 19% increase, so the trial cannot exclude a modest effect either way.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.